Abstract | PURPOSE: METHODS: Clinical data, including longitudinal tumor volumes in patients treated by bevacizumab (n = 13), everolimus (n = 7) or both (n = 2), were analyzed by means of mathematical modeling techniques. Together with clinical data, data from the literature were also integrated to account for drugs mechanisms of action. RESULTS: CONCLUSION: The developed model successfully describes tumor volume growth before and during bevacizumab and/or everolimus treatment. It might constitute a rational tool to predict patients' response to these drugs, thus potentially improving management of this disease.
|
Authors | Aziz Ouerdani, Stéphane Goutagny, Michel Kalamarides, Iñaki F Trocóniz, Benjamin Ribba |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 77
Issue 6
Pg. 1263-73
(06 2016)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 27146400
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Vascular Endothelial Growth Factor A
- Bevacizumab
- Everolimus
- TOR Serine-Threonine Kinases
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, pharmacokinetics, therapeutic use)
- Bevacizumab
(administration & dosage, pharmacokinetics, therapeutic use)
- Child
- Child, Preschool
- Everolimus
(administration & dosage, pharmacokinetics, therapeutic use)
- Female
- Humans
- Male
- Markov Chains
- Middle Aged
- Models, Biological
- Neurofibromatosis 2
(complications, drug therapy, metabolism)
- Neuroma, Acoustic
(complications, drug therapy, metabolism)
- TOR Serine-Threonine Kinases
(metabolism)
- Time Factors
- Tumor Burden
(drug effects)
- Vascular Endothelial Growth Factor A
(metabolism)
- Young Adult
|